Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Megestrol acetate
Drug ID BADD_D01372
Description 17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Indications and Usage For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.
Marketing Status Prescription; Discontinued
ATC Code G03AC05; G03DB02; L02AB01
DrugBank ID DB00351
KEGG ID D00952
MeSH ID D019290
PubChem ID 11683
TTD Drug ID Not Available
NDC Product Code 49884-289; 0121-4776; 72969-102; 17856-0907; 49884-290; 0009-5030; 60429-433; 77044-5047; 24979-041; 51927-1670; 49884-230; 68094-361; 63629-7631; 0904-3571; 63739-549; 46439-8722; 0555-0607; 0121-0945; 63629-2221; 64380-158; 49884-907; 71205-943; 55154-5776; 63629-2219; 66689-020; 81646-120; 50383-859; 63629-2220; 60432-126; 51991-313; 0555-0606; 43744-363; 63592-0109; 64380-159; 68094-250; 0904-7072
Synonyms Megestrol Acetate | Acetate, Megestrol | Lin-Megestrol | Lin Megestrol | LinMegestrol | Maygace | Megace | Megostat | Megestat | Megefren | Mestrel | Nu-Megestrol | Nu Megestrol | NuMegestrol | Borea | Apo-Megestrol | Apo Megestrol | ApoMegestrol
Chemical Information
Molecular Formula C24H32O4
CAS Registry Number 595-33-5
SMILES CC1=CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oral candidiasis11.03.03.004; 07.05.07.001--Not Available
Pain08.01.08.004--
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pollakiuria20.02.02.007--
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.0010.001972%Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Salivary hypersecretion07.06.01.009--Not Available
Sarcoma16.33.01.002; 15.09.03.002--Not Available
Secondary adrenocortical insufficiency05.01.02.003; 14.11.01.014--Not Available
Seizure17.12.03.001--
Skin disorder23.03.03.007--Not Available
Steroid withdrawal syndrome08.06.02.013; 05.01.02.007; 19.04.02.0140.001972%Not Available
Stress19.06.02.004--Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tumour flare16.32.03.001--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Uterine haemorrhage24.07.03.004; 21.07.01.005--
Vomiting07.01.07.003--
Weight increased13.15.01.0060.002959%
Deep vein thrombosis24.01.02.0030.001972%Not Available
Affect lability19.04.01.001--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages